Filing identity and reporting period
Important entity mismatch: The request identifies Glucotrack, Inc., but the filing text is for Integrity Applications, Inc. (OTC: IGAP), a development-stage company whose product is named GlucoTrack. The filing is a Form 10-K for the fiscal year ended December 31, 2013, filed March 28, 2014; it is not a Q4-only report.
Business context and reporting period
Integrity Applications develops the GlucoTrack DF-F, a non-invasive, spot blood-glucose monitor that measures through an earlobe clip using ultrasound, electromagnetic and thermal technologies. It received CE Mark approval on June 4, 2013, but had not started product sales and had no U.S. marketing approval. The company reported as a development-stage business operating primarily through its Israeli subsidiary.
Key financial metrics
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.987 million | $1.921 million |
| General and administrative expense | $1.041 million | $0.853 million |
| Operating loss | $3.028 million | $2.774 million |
| Net loss | $9.797 million | $2.772 million |
| Net cash used in operating activities | $3.218 million | $2.297 million |
| Cash and cash equivalents at year-end | $2.386 million | $0.543 million |
Gross margin and operating margin are not meaningful because the company had no revenue. FY 2013 net loss included $6.251 million of warrant fair-value expense and $0.391 million of issuance costs allocated to warrants with down-round protection. These non-cash and financing-related items drove most of the year-over-year increase in reported net loss.
At December 31, 2013, total current assets were $2.479 million and current liabilities were $0.311 million, implying working capital of approximately $2.168 million. Total liabilities were $9.457 million, including $8.217 million of warrant liability and $0.693 million of long-term stockholder loans. There was no bank borrowing outstanding at year-end; an approximately $86,000 credit line was available but secured by deposits. Temporary equity included $4.363 million of convertible preferred stock. Stockholders’ deficit was $11.063 million.
Cash from financing activities was $5.056 million in 2013, including approximately $5.4 million net proceeds from the preferred-stock-and-warrant offering, partly offset by $288,248 in preferred dividends. Cumulative losses since inception were $25.087 million and cumulative negative operating cash flow was $14.792 million.
Material changes versus the prior comparable period
- Net loss increased from $2.772 million to $9.797 million, principally because of the warrant fair-value charge and related issuance costs; operating loss rose more modestly, from $2.774 million to $3.028 million.
- Operating cash use increased from $2.297 million to $3.218 million. Year-end cash rose to $2.386 million from $0.543 million, supported by the 2013 financing.
- R&D expense increased about 3%, mainly due to travel associated with post-market clinical follow-up trials. General and administrative expense increased about 22%, mainly from professional, investor-relations, public-relations and public-company costs.
- The company obtained CE Mark approval in 2013 and shifted additional attention toward production and distribution preparation, but had not yet generated sales.
Outlook, commentary, risks and unusual items
- Management anticipated first sales in certain distributor territories as early as the first half of 2014 and U.S. clinical trials as early as 2014, conditional on FDA protocol approval. These were expectations, not assured outcomes.
- As of March 20, 2014, cash was approximately $1.78 million; management estimated it would fund operations for about five months from the report date. The company said it would need additional capital, with no assurance financing would be available on acceptable terms.
- The independent auditor cited substantial doubt about the company’s ability to continue as a going concern. The statements contain no adjustments for the possible outcome of that uncertainty.
- Commercialization depends on third-party manufacturers and exclusive distributors. Manufacturing agreements for anticipated mass production were still under negotiation, and distributor execution, demand, reimbursement and regulatory requirements remained uncertain.
- The U.S. device was not approved for sale. Management believed a PMA pathway and human clinical trials were likely; FDA trial timing and requirements were uncertain. EU member states could also request additional data despite CE Mark approval.
- Preferred stock carries a cumulative 5% dividend, conversion and down-round protections, covenants restricting certain actions, and potential redemption or increased-dividend provisions upon specified trigger events. Down-round warrants were recorded as a derivative liability and remeasured through earnings.
- A disputed Dimri anti-dilution claim was in arbitration, with settlement discussions ongoing. The company could not estimate a reasonably possible loss and recorded no provision.
- Other notable exposures include OCS royalties of 3%–5% of qualifying future product sales until the grant amount plus interest is repaid, and restrictions on transferring OCS-funded technology or manufacturing outside Israel. No OCS royalties had been accrued or paid through 2013.
Most important facts for investors to verify
- Confirm the intended issuer: this filing names Integrity Applications, Inc., not Glucotrack, Inc.
- Check subsequent filings for actual product sales, distributor orders, manufacturing contracts, FDA trial progress and additional regulatory approvals.
- Verify the company’s post-March 2014 cash position, financing activity, cash burn and ability to continue as a going concern.
- Review the preferred-stock and warrant terms, including dilution, dividend, redemption, covenant and down-round provisions, and assess the warrant liability’s sensitivity to valuation assumptions.
- Track the Dimri arbitration or settlement and any resulting share issuance, dilution or other liability.
- Assess whether reimbursement, manufacturing capacity and distributor performance support viable commercial adoption; the filing’s cost-saving estimates are company assumptions, not reported sales results.